Fibrosis: Clinical Trials

78 trials for Fibrosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

78 terminated. 78 Phase 2, 9 Phase 1, 7 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 278Terminated 78
Phase 19Terminated 9
Phase 37Terminated 7

Follow Fibrosis: new trials by email Literature Review of Fibrosis trials Research Report on Fibrosis

Trials (filtered) newest first · largest first

All 78 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy
VS-01 on top of SOC (Active Treatment Group), SOC - Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF)
Phase 2TerminatedGenfit32025-08-252026-01-12
NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients
MAP-Target Algorithm - Acute Kidney Injury, Cirrhosis
Phase 2 / Phase 3TerminatedUniversity of California, San Francisco142024-02-012026-09-24
A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly
Placebo, Avenciguat - Hypertension, Portal, Liver Cirrhosis
Phase 2TerminatedBoehringer Ingelheim222024-01-032025-06-12
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
PLN-74809, Placebo - Idiopathic Pulmonary Fibrosis
Phase 2TerminatedPliant Therapeutics, Inc.3202023-11-162026-08-05
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
VS-01 on top of SOC, SOC (Control Group) - Acute-On-Chronic Liver Failure, Ascites
Phase 2TerminatedGenfit152023-07-022026-07-23
Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part A: zibotentan (dose B) + dapagliflozin, Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) - Liver Cirrhosis
Phase 2TerminatedAstraZeneca2052022-10-312026-09-25
A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
HZN-825, Placebo - Idiopathic Pulmonary Fibrosis
Phase 2TerminatedAmgen1532022-01-202025-12-03
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
Durvalumab, Tremelimumab, Liver Transplant - Hepatocellular Carcinoma, Cirrhosis
Phase 2TerminatedUniversity of Cincinnati82021-12-072026-05-06
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
APX-115, Placebo - COVID-19
Phase 2TerminatedAptabio Therapeutics, Inc.162021-10-202026-06-10
The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis
Danazol, Placebo - Pulmonary Fibrosis, Telomere Shortening
Phase 2TerminatedThe University of Queensland292021-09-072025-08-05
Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy
AXA1665, Placebo - Hepatic Encephalopathy
Phase 2TerminatedAxcella Health, Inc122021-06-292022-07-27
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
Ixazomib - Systemic Sclerosis, Scleroderma
Phase 2TerminatedMichael M. Pham42021-04-282025-04-06
Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy
RBX7455, Placebo - Hepatic Encephalopathy, Cirrhosis, Liver
Phase 2TerminatedOchsner Health System52021-03-012023-10-03
Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis
Align Probiotic Supplement Capsule, Placebos - Fatty Liver Disease, Fibrosis, Liver
Phase 1 / Phase 2TerminatedCorewell Health East142021-01-122022-09-27
LYT-100 in Post-acute COVID-19 Respiratory Disease
LYT-100, Placebo - Covid19, Post-acute COVID-19 Respiratory Disease
Phase 2TerminatedPureTech1852020-12-112026-06-23
Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars
PRP Injection, Saline Injection - Hypertrophic Scar
Phase 2TerminatedVanderbilt University Medical Center32020-09-182023-01-09
Losartan to Improve Hip Microfracture
Losartan, Placebo - Hip Osteoarthritis, Hip Impingement Syndrome
Phase 1 / Phase 2TerminatedSteadman Philippon Research Institute12020-08-072023-10-30
Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.
Ularitide, Placebo - Cirrhosis, Liver, Ascites Hepatic
Phase 2TerminatedUniversity of Aarhus172020-08-012023-05-18
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
belapectin, Placebo - Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis
Phase 2 / Phase 3TerminatedGalectin Therapeutics Inc.3572020-06-252026-06-30
Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC
Obeticholic acid, Bezafibrate 200 MG, OCA Placebo - Primary Biliary Cholangitis
Phase 2TerminatedIntercept Pharmaceuticals752019-10-022026-07-16

Showing 20 of 78. Sign in to see all of them.

Narrower conditions

Liver Cirrhosis (19)  ·  Pulmonary Fibrosis (15)  ·  Liver Cirrhosis, Biliary (12)  ·  Idiopathic Pulmonary Fibrosis (9)  ·  Hypertension, Portal (8)  ·  Non-alcoholic Fatty Liver Disease (7)  ·  Ascites (5)  ·  Lung Diseases, Interstitial (5)  ·  Carcinoma, Hepatocellular (4)  ·  Cicatrix (4)  ·  Hepatic Encephalopathy (4)  ·  Keloid (4)  ·  Liver Diseases (4)  ·  Cicatrix, Hypertrophic (3)

Broader conditions

Pathological Conditions, Signs and Symptoms (78)  ·  Pathologic Processes (75)  ·  Digestive System Diseases (43)  ·  Liver Diseases (38)  ·  Respiratory Tract Diseases (19)  ·  Lung Diseases (18)  ·  Bile Duct Diseases (13)  ·  Biliary Tract Diseases (13)  ·  Cholestasis (12)  ·  Cholestasis, Intrahepatic (12)  ·  Liver Cirrhosis (12)  ·  Lung Diseases, Interstitial (12)  ·  Skin and Connective Tissue Diseases (11)  ·  Cicatrix (7)

Interventions

simtuzumab (4)  ·  Losartan (3)  ·  Bosentan (2)  ·  CC-90001 (2)  ·  Danazol (2)  ·  Sorafenib (2)  ·  obeticholic acid (2)  ·  (2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2H-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid (1)  ·  2-methyl-3-(2-((4-nitrooxybutyloxy)carbonyl)vinyl)phenyl ursodeoxycholic acid ester (1)  ·  3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (1)  ·  4-(9-(tetrahydrofuran-3-yl))-8-(2,4,6-trifluorophenylamino)-9H-purin-2-ylaminocyclohexan-1-ol (1)  ·  Acetylcysteine (1)  ·  Albumins (1)  ·  Bevacizumab (1)  ·  Bezafibrate (1)

Sponsors

Gilead Sciences (6)  ·  Celgene (3)  ·  Novartis Pharmaceuticals (3)  ·  Genfit (2)  ·  Intercept Pharmaceuticals (2)  ·  Tirgan, Michael H., M.D. (2)  ·  University of Padova (2)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)  ·  Ainos, Inc. (f/k/a Amarillo Biosciences Inc. (1)  ·  Alicia Gerke (1)  ·  Amgen (1)  ·  Aptabio Therapeutics, Inc. (1)  ·  Arena Pharmaceuticals (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  AstraZeneca (1)

Countries

United States (52)  ·  United Kingdom (21)  ·  France (16)  ·  Germany (16)  ·  Spain (16)  ·  Canada (14)  ·  Italy (12)  ·  Australia (11)  ·  Belgium (9)  ·  Poland (9)  ·  South Korea (8)  ·  Netherlands (7)  ·  Austria (5)  ·  Japan (5)  ·  Puerto Rico (5)

Top investigators

Michael H Tirgan, MD (2)  ·  Alain Hendlisz, MD (1)  ·  Alexander Meves, MD (1)  ·  Alicia K Gerke, MD (1)  ·  Andres Duarte-Rojo, M.D. (1)  ·  Arena CT.gov Administrator (1)  ·  Bhavisha Patel, M.D. (1)  ·  Davendra Sohal, MD (1)  ·  David A Shapiro, MD (1)

Results publications

PMID 29990488, PMID 33307033, PMID 36750244, PMID 22383668, PMID 23499151, PMID 23664631, PMID 25500425, PMID 25543678, PMID 28818518, PMID 29486918, PMID 34504196, PMID 34857525, PMID 34894681, PMID 35058236, PMID 38484130, PMID 40692836, PMID 41807015

NIH funding

2016 (3), 2018 (2), 2023 (2), 2008 (1), 2009 (1), 2015 (1), 2019 (1), 2025 (1), R21DK092567 (1)